Novel Insights Into the Pathogenesis and Therapy of Circulatory Shock

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 2, Issue 1, 1998, Pages 31-45

  Steingrub, Jay S ^a  

^a BAYSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84993687281     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/108925329800200103     Document Type: Article

References (114)

1. Maitra SR, Geller ER, Pan W.: Altered cellular calcium regulation and hepatic glucose production during hemorrhagic shock. Circ Shock 38:14-21, 1992
2. Maitra SR, Krikhely M., Duchavsky SA: Beneficial effects of diltiazam in hemorrhagic shock. Circ Shock 33:121-125, 1991
3. Sayeed MM, Maitra SR: Effect of diltiazam on altered cellular calcium regulation during endotoxic shock. Am J Physiol 253 (Regulatory Integrative Comp Physiol 22):R549-R554, 1987
4. Braughler JM: Calcium and lipid peroxidation, in Halliwell B (ed): Oxygen Radicals and Tissue Injury. Proceedings of a Brook Lodge Symposium. Bethesda, MD, Federation of American Societies for Experimental Biology, 1988, pp 99-104
5. Reilly PM, MacGowan S., Miyachi M.: Mesenteric vasoconstriction in cardiogenic shock in pigs. Gastroenterology 102: 1968-1979,1992
6. Cullen JJ, Ephgrave KS, Broadhurst KA: Captopril decreases stress ulceration without affecting gastric perfusion during canine hemorrhage shack. J Trauma 37:43-49, 1994
7. Bitterman H., Phillips GR III, Gragon G.: Potentiation of the protecting effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock. J Pharmacol Exp Ther 242:8-14, 1987
8. Zambon A., Waxman K., Daughters K.: ATP-MgCl2 added to resuscitation improves survival in an experimental model of hemorrhagic shock. Resuscitation 28:253-257, 1994
9. Ohkawa M., Clemens MG, Chaudry IH: Studies on the mechanisms of beneficial effects of ATP-MgCl2 following hepatic ischemia. Am J Physiol 244:R695-R702, 1983
10. Wang P., Ba ZF, Morrison MH: Mechanism of the beneficial effects of ATP-MgCl2 following trauma, hemorrhage and resuscitation: Down-regulation of inflammatory cytokine (TNF, IL-6) release. J Surg Res 52:364-371, 1992
11. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 320:365-376, 1989
12. Botha AJ, Moore FA, Moore EE: Post-injury neutrophil priming and activation states: Therapeutic challenges. Shock 3:157-166, 1995
13. Jeroudi MO, Triana FJ, Patel BS: Effects of superoxide dismutase and catalase given separately on myocardial “stunning.” Am J Physiol 259:H889-H901, 1990
14. Rhee P., Waxman K., Clark L.: Superoxide dismutase polyethylene glycol improves survival in hemorrhagic shock. Am Surg 57:747-750, 1991
15. Tan LR, Waxman K., Clark L.: Superoxide dismutase and allopurinol improve survival in an animal model of hemorrhagic shock. Am Surgeon 59:780-797, 1993
16. Bolli R.: Oxygen-derived free radicals and post-ischemic myocardial dysfunction ('stunned myocardium'). J Am Coll Cardiol 12:239-249, 1988
17. Coghlan JG, Flitter WD, Clutton SM: Allopurinol pretreatment improves post-operative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 107:248-256, 1994
18. Movahed A., Nair KG, Ashavaid TF: Free radical generation and the role of allopurinol as a cardioprotective agent during coronary artery bypass grafting surgery. Can J Cardiol 12:138-144, 1996
19. Drossos G., Lazou A., Panagopowos P.: Deferoxamine cardioplegia reduces superoxide radical production in human myocardium. Ann Thorac Surg 59:169-172, 1995
20. Korthius RJ, Anderson DC, Granger DN: Role of neutrophil-endothelial cell adhesion in inflammatory disorders. J Crit Care 9:47-71, 1994
21. Granger DN, Kvietys PR, Perry MA: Leukocyte-endothelial cell adhesion induced by ischemia and reperfusion. Can J Physiol Pharmacol 71:67-75, 1993
22. Huang Gt-J, Eckmann L., Savidge T.: Infection of human intestinal epithelial cells with invasive bacteria upregulates apical intercellular adhesion inolecular-1 (ICAM-1) expression and neutrophil adhesion. J Clin Invest 98:572-583, 1996
23. Sessler CN, Windsor Acj, Schwartz M.: Circulating ICAM-1 is increased in septic shock. Am J Respir Crit Care Med 151:1420-1427, 1995
24. Marzi I., Bauer C., Hower R.: Leukocyte-endothelial cell interactions in the liver after hemorrhagic shock in the rat. Circ Shock 40:105-114, 1993
25. Kubes P., Ibbotson G., Russell J.: Role of platelet-activating factor in ischemia/reperfusion induced leukocyte adherence. Am J Physiol 259:G300-G305, 1990
26. Ramson JL, Hook BG, Kinkel S.: Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 67:1016-1023, 1983
27. Engler RL, Dahlgren MD, Morris D.: Role of leukocytes on the response to acute myocardial ischemia and reflow in dogs. Am J Physiol 251:H314-H323, 1986
28. Wainwright CL, Parratt JR, Bigand M.: The effects of PAF antagonist on arrhythmias and platelets during acute myocardial ischemia and reperfusion. Eur Heart J 10:235-243, 1986
29. Torras J., Bordalba J., Seron D.: Protective effect of PAF antagonist BN 52021 in an experimental renal warm ischemia model. Transpl Int 6:236-238, 1993
30. Mullane KM: Eicosanoids in myocardial ischemia reperfusion injury, in Lewis A (ed): Advances in Inflammation Research. NewYork, NY, Raven, 1988, pp 191-214
31. Semb AG, Forsdahl K., Vaage J.: Granulocyte and eicosanoid gradients across the coronary circulation during myocardial reperfusion in cardiac surgery. Eur J Cardiothorac Surg 4:543-548, 1990
32. Asako H., Granger DN, Korthuis RJ: Phalloidin reduces leukocyte emigration and vascular permeability in post-capillary venules. Am J Physiol 263:H1637-H1642, 1992
33. Kurose I., Anderson DC, Miyasaka M.: Molecular determinants of reperfusion-induced leukocyte adhesion and vascular protein leakage. Circ Res 74:336-343, 1994
34. Huie RE, Padnaja S.: The reaction of NO with superoxide. Free Rad Res Comm 18:195-200, 1993
35. Radomski MW, Palmer Rmj, Moncada S.: An L-arginine/ nitric oxide pathway present in human platelets regulates aggregation. Proc Nat'l Acad Sci USA 87:5193-5197, 1990
36. Clancy RM, Leszczynska-Piziak J., Abramson SB: Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest 90:1116-1121, 1992
37. Kurose I., Wolf R., Grisham MB: Microvascular response to inhibition of nitric oxide production: Role of active oxidants. Circ Res 76:30-39, 1995
38. Johnson G., Furlan LE, Lefer AM: Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats. Circ Res 66:1362-1370, 1990
39. Fourrier F., Chopin C., Huart J-J.: Double blind, placebo controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882-888, 1993
40. Marzi I., Maier M., Herzog C.: Influence of pentoxifylline and albifylline on liver microcirculation and leukocyte adhesion after hemorrhagic shock in the rat. J Trauma 40:90-96, 1996
41. Ellerman J., Gründer W., Keller T.: Effect of pentoxifylline on the ischemic rat kidney monitored by 31p NMR spectroscopy in vivo. Biomed Miochin Acta 47:515-521, 1988
42. Daughters K., Cinat M., Waxman K.: Amrinone improves survival in hemorrhagic shock. Am Surgeon 60:728-731, 1994
43. Calandra T., Baumgartner JD, Grau GE: Prognostic value of tumor necrosis factor-cachectin, interleukin-I, interferon alpha, and interferon-gamma in the serum of patients with septic shock. J Infect Dis 161:982-987, 1990
44. Zabel P., Schade U., Schlaak M.: Inhibition of endogenous TNF formation by pentoxiftlline. Immunobiology 187:447-463, 1993
45. Jansen Njg, van Oeveren W., vd Broek L.: Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. J Thorac Cardiovasc Surg 102:515-525, 1991
46. Zimmerman BJ, Holt JW, Paulson JC: Molecular determinants of lipid mediator-indiced leukocyte adherence and emigration in rat mesenteric venules. Am J Physiol 266:H847-H853, 1994
47. Gulick TS, Chang MK, Pieper SJ: Interleukin-1 and tumor necrosis factor inhibit cardiac myocyte B-adrenergic responsiveness. Proc Nat'l Acad Sci 86:6753-6757, 1989
48. Fowler MB, Laser JA, Hopkins GL: Assessment of the B-adrenergic receptor pathway in the intact failing human heart: Progressive receptor down-regulation and subsensitivity to agonist response. Circulation 74: 1290-1302, 1989
49. Kawamura T. Wakusawa R, Okada K.: Elevation of cytokines during open heart surgery with cardiopulmonary bypass: Participation of interleukin 8 and 6 in reperfusion injury. Can J Anaesth 40:1016-1021, 1993
50. Finn A., Norik S., Klein N.: Interleukin-8 release and neutrophil degranulation after paediatric cardiopulmonary bypass. J Thorac Cardiovasc Surg 105:234-241, 1993
51. Jorens PG, Jongh RD, Backer WD: Interleukin-8 production in patients undergoing cardiopulmonary bypass: The influence of pretreatment with methylprednisone. Am Rev Respir Dis 148:890-895, 1993
52. Kirklin JK, Westaby S., Blackstone EH: Compliment and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86:845-857, 1983
53. Frering B., Philip J., Dehoux M.: Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg 108:636-641, 1994
54. Chenoweth DE, Cooper SW, Hugli TE: Complement activation during cardiopulmonary bypass: Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 304:497-503, 1981
55. Rocke DA, Graffin SL, Wells MT: Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 93:832-837, 1987
56. Watrarida S., Mori A., Onoe M.: A clinical study on the effects of pulsatile cardiopulmonary bypass on the blood endotoxin levels. J Thorac Cardiovasc Surg 108: 620-625, 1994
57. Riddington DW, Venkatesh B., Boivin CM: Intestinal permeability, gastric intramucosal pH and systemic endotoxemia in patients underoing cardiopulmonary bypass. JAMA 275:1007-1012, 1996
58. Martinez-Pellus AE, Merino P., Bru M.: Can selective decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass? Crit Care Med 21:1684-1691, 1993
59. Goldie AS, Fearon Kch, Ross JA: Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 274:172-177, 1995
60. Bennett-Guerrero E., Ayuso L., Hamilton-Davies C.: Relationship of pre-operative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 277:646-650, 1997
61. Van Oeveren W. Wildevuur CRH: Blood compatibility of cardiopulmonary bypass circuits. Perfusion 12:237-244, 1987
62. Van Oeveren W, Jansen Njg, Bidstrup BP: Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 44:640-645, 1987
63. Riegel W., Spillner G., Schlosser V., Horl WH: Plasma levels of main granulocyte components during cardiopulmonary bypass. J Thorac Cardiovasc Surg 95:1014-1019, 1988
64. England MD, Cavarocchi NC, O'Brien JF: Influence of antioxidants (mannitol and allopurinol) on oxygen free radical generation during and after cardiopulmonary bypass. Circulation 74:I11134-I11137, 1986
65. Castelli P., Condemi AM Brambillasca C: Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J Cardiovasc Pharmacol 25:119-125, 1995
66. Boyd MR, Catignani GL Sasame HA: Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E, dietary fat and oxygen. Am Rev Respir Dis 120:93-99, 1979
67. Menasché P., Antebi H. Alcindor L-G: Iron chelation by deferoxamine inhibits lipid perioxidation during cardiopulmonary bypass in humans. Circulation 82:340-346, 1990 (suppl 4)
68. Mandell G, Novick W (eds): Proceedings of a symposium pentoxifylline and leukocyte function. Somerville, NJ, Hoechst-Roussel Pharm Inc, 1988, pp 199-210
69. Toombs CF, McGee DS, Johnston WE: Myocardial protective effects of adenosine. Infarct size reduction with pre-treatment and continued receptor stimulation during ischemia. Circulation 86:986-994, 1992
70. Vinten-Johansen J., Nakanishi K., Zhao ZQ: Acadesine improves surgical myocardial protection with blood cardioplegia in ischemically injured canine hearts. Circulation 88:350-359, 1993 (supp)
71. Nakanishi K., Vinten-Johansen J., Lefer DJ: Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am J Physiol 263:H1650-H1658, 1992
72. Sato Hiroki, Zhao ZQ, McGee S.: Supplemental L-arginine during cardioplegic arrest and reperfusion avoids regional post-ischemic injury. J Thorac Cardiovasc Surg 110:302-314, 1995
73. Akira S., Hirano T., Taga T.: Biology of multi-functional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEBJ 4:2860-2867,1990
74. Morrison DC, Danner RL, Dinarello CA: Bacterial endotoxins and pathogenesis of gram-negative infections: Current status and future direction. J Endotoxin Res 1:71-83, 1994
75. Ziegler EJ, Fisher CJ, Sprung CL: Treatment of gram-negative bactermia and septic shock with HA-IA human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429-436, 1991
76. Bone RC, Balk RA, Fein AM: A second large controlled study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23:994-1006, 1995
77. Schedel I., Driekhausen U., Nentwig B.: Treatment of gram negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Crit Care Med 19:1104-1113, 1991
78. Warren HS, Amato SF, Fitting C.: Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 177:89-97, 1993
79. Evans TJ, Carpenter A., Moyes D.: Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis.J Infect Dis 171:153-160, 1995
80. Marra MN, Thornton MB, Snable JL: Endotoxin-binding and neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-IA and E5. Crit Care Med 22:559-565, 1994
81. Aoki H., Kodama M., Tani T.: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 167:412-417, 1994.
82. Grootendorst AF van Bommel Efh, van der Hoven B.: High volume hemofiltration improves hemodynamics of endotoxin indiced shock in the pig. J Crit Care 7:67-75, 1992
83. Hinshaw LB, Emerson Tej, Taylor Fbj: Lethal staphylococcus aureus-induced shock in primates: Prevention of death with anti-TNF antibody. J Trauma 23:568-573, 1992
84. Abraham E., Wunderink R., Silverman H.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 273:934-941, 1995
85. Gohen J., Carlet J.: INTERSEPT. An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor α in patients with the sepsis. Crit Care Med 24:1431-1440, 1996
86. Fisher CJ Jr, Agosti JM, Opal SM: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334:1697-1702, 1996
87. Lundblad R., Estrom P., Giercksky KE: Pentoxifylline improves survival and reduces TNF, IL-6, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Shock 3:210-215, 1995
88. Zeni F., Pain P., Vindimian M.: Effects of pentaxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: Results from a double-blind, randomized, placebo-controlled study. Crit Care Med 24:207-214, 1996
89. Barton P., Garcia J., Kouatli A.: Hemodynamic effects of IV milrinone lactate in pediatric patients with septic shock: A prospective double-blind, randomized, placebo-controlled, interventianal study. Chest 109:1302-1312, 1996
90. Fisher CJ, DhainautJF, Opal SM: Recombinant human interteukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 271: 1836-1843, 1994
91. Silva AT, Cohen J.: Role of interferon gamma in experimental gram negative sepsis. J Infect Dis 166:331-335, 1992
92. van der Poll T., Levi M., Hack C.E.: Elimination of interleukin-6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 179: 1253-1262, 1994
93. Sekido N., Mukaida N., Harada A.: Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 365:654-657, 1993
94. Gérard C., Bruyns C., Marchant A.: Interleukin-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177:547-550, 1993
95. Fein AM, Bernard GR, Criner GJ: Treatment of severe systemic inflammation response syndrome and sepsis with a novel bradykinin antagonist, Deltibant (CP-0127): Results of a randomized, souble-blind, placebo-controlled trial. JAMA 277:482-487, 1997
96. Dhainaut JF, Tenaillen A., Tulzo YL: Platelet activating factor receptor antagonist BN52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22:1720-1728, 1994
97. Gourlay ML, Dhainaut JF, Tenaillon A.: Confirming phase III clinical trial to study the efficacy of a PAF antagonist, BN52021, in reducing mortality of patients with severe gram-negative sepsis. Shock 3:65, 1995 (suppl)
98. Bone RC: Phospholipids and their inhibitors: A critical evaluation of their role in the treatment of sepsis. Crit Care Med 20:884-890, 1992
99. Metz CA, Sheagren JN: Ibuprofen in animal models of septic shock. J Crit Care 5:206-212, 1990
100. Bernard GR, Wheeler AP, Russell JA: The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 336:912-918, 1997
101. Yu M., Tomasa G.: A double, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 21:1635-1642, 1993
102. Hollenberg SM, Cunnion RE, Zimmerberg J.: Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamine in septic rats. Am J Physiol 264:H660-H663, 1993
103. Petros A., Lamb G., Leone A.: Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28:34-39, 1994
104. Stamler JS: Redox signaling: Nitrosylation and related target interactions of nitric oxide. Cell 78:931-936, 1994
105. Mulligan MS, Paulson JC, DeFrees S.: Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature 364:149-151, 1993
106. Goode HF, Webster NR: Free radicals and antioxidants in sepsis. Crit Care Med 21:1770-1776, 1993
107. Spies CD, Reinhart K., Witt I.: Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: Results from a prospective, randomized, double-blind study. Crit Care Med 22:738-746, 1994
108. Tani T., Aoki H., Yoshioka T.: Treatment of septic shock with a protease inhibitor in a canine model: A prospective, randomized, controlled trial. Crit Care Med 21:925-930, 1993
109. Silverman HJ, Penaranda R., Orens JB: Impaired beta-adrenergic stimulation of cyclic adenosine monophosphate in human septic shock: Association with myocardial hyporesponsiveness to catecholamines. Crit Care Med 21:31-39, 1993
110. Liao J., Keiser JA, Scales WE: Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Physiol 268:R896-R901, 1995
111. Elenkov IJ, Hasko G., Kovacs KJ: Modulation of lipopolysaccharide-induced tumor necrosis factor a production by selective α and β adrenergic drugs in mice. J Neuroimmunol 61:123-131, 1996
112. van der Poll T., Coyle SM, Barbosa K.: Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 97:713-719, 1996
113. Vizi ES, Harsing LJ Jr, Gaal J.: CH-38083, a selective, potent antagonist of alpha-2 adreno receptor. J Pharmacol Exp Ther 238:701-706, 1986
114. Waxman K.: Preface: What mediates tissue injury after shock? New Horizons 4:151-152, 1996